+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psoriatic Arthritis - Epidemiology Forecast - 2032- Product Image
Psoriatic Arthritis - Epidemiology Forecast - 2032- Product Image
Sale

Psoriatic Arthritis - Epidemiology Forecast - 2032

  • PDF Icon

    Report

  • 141 Pages
  • September 2022
  • Region: Global
  • DelveInsight
  • ID: 5387735
UP TO OFF until Dec 31st 2024
Description Jump to:
This Psoriatic Arthritis (PsA) - Epidemiology Forecast - 2032 report delivers an in-depth understanding of the historical and forecasted epidemiology of psoriatic arthritis (PsA) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Psoriatic Arthritis (PsA): Disease Understanding

Psoriatic Arthritis (PsA) Overview

Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis (PsA) resembles rheumatoid arthritis (RA) in symptoms characterized by joint inflammation. However, psoriatic arthritis (PsA) affects fewer joints than RA and does not produce the typical RA antibodies.

In 1956, Wright described arthritis associated with psoriasis. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of psoriatic arthritis (PsA) is poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.

The etiology and pathogenesis of psoriatic arthritis (PsA) involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of PsA patients have at least one first-degree relative with psoriasis or psoriatic arthritis (PsA). Genes associated with psoriatic arthritis (PsA) include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression, and signaling T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma induces psoriatic skin lesions flares, known as the Koebner phenomenon. Evidence suggests that joint trauma may cause a flare of arthritis, referred to as the “internal” or “deep” Koebner phenomenon.

Psoriatic arthritis (PsA) shares some clinical features with other inflammatory arthritides, including RA, reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnosis. Unlike psoriatic arthritis (PsA), RA is symmetrical and generally spares the DIP joints. AS has an earlier onset age than psoriatic arthritis (PsA), and sacroiliac involvement is usually symmetric rather than asymmetric.

Psoriatic arthritis (PsA) may range from mild to severe, and its treatment is crucial despite the severity. If left untreated, psoriatic arthritis (PsA) can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating psoriatic arthritis (PsA) may also help reduce inflammation that could lead to other comorbidities. However, no cure for psoriatic arthritis (PsA) exists, so treatment goals are to slow disease progression, improve QoL, lessen pain, and preserve the range of motion. In most PsA patients, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs, if a patient does not respond adequately.

Epidemiology

Psoriatic arthritis (PsA) epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted psoriatic arthritis (PsA) epidemiology segmented as the prevalent cases of psoriatic arthritis (PsA), diagnosed cases of psoriatic arthritis (PsA), gender-specific cases of psoriatic arthritis (PsA), age-specific cases of psoriatic arthritis (PsA) and severity-specific cases of psoriatic arthritis (PsA). The report includes the prevalent psoriatic arthritis (PsA) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise psoriatic arthritis (PsA) Epidemiology

The epidemiology segment also provides psoriatic arthritis (PsA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 1.5 million in 2021.

As per the estimates, the US had the highest total patient population of psoriatic arthritis (PsA) in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.

Scope of the Report

  • Psoriatic arthritis (PsA) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
  • Psoriatic arthritis (PsA) epidemiology report and model provide an overview of the risk factors and global trends of psoriatic arthritis (PsA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of psoriatic arthritis (PsA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of psoriatic arthritis (PsA).
  • The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by prevalent cases of psoriatic arthritis (PsA) in the 7MM.
  • The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by diagnosed cases of psoriatic arthritis (PsA) in the 7MM.
  • The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by age-specific cases of psoriatic arthritis (PsA) in the 7MM.
  • The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by gender-based cases of psoriatic arthritis (PsA) in the 7MM.
  • The report segments psoriatic arthritis (PsA) epidemiology by severity-specific cases of psoriatic arthritis (PsA) in the 7MM.

Report Highlights

  • 11-year forecast of psoriatic arthritis (PsA) epidemiology
  • 7MM coverage
  • Prevalent cases of psoriatic arthritis (PsA)
  • Diagnosed cases of psoriatic arthritis (PsA)
  • Age-specific cases of psoriatic arthritis (PsA)
  • Gender-specific cases of psoriatic arthritis (PsA)
  • Severity-specific cases of psoriatic arthritis (PsA)

KOL Views

The publisher interviews KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the change in the patient population in psoriatic arthritis (PsA) during the forecast period (2019-2032)?
  • What are the key findings pertaining to psoriatic arthritis (PsA) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients with psoriatic arthritis (PsA) across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
  • What are the disease risk, burdens, and unmet needs of psoriatic arthritis (PsA)?
  • What are the currently available treatments for psoriatic arthritis (PsA)?

Reasons to Buy

Psoriatic Arthritis (PsA) epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global psoriatic arthritis (PsA) market
  • Quantify patient populations in the global psoriatic arthritis (PsA) market to improve product design, pricing, and launch plans
  • Understand the magnitude of psoriatic arthritis (PsA) population by its prevalent cases
  • Understand the magnitude of psoriatic arthritis (PsA) population by its diagnosed cases
  • Understand the magnitude of psoriatic arthritis (PsA) population by its age-specific cases
  • Understand the magnitude of psoriatic arthritis (PsA) population by its gender-specific cases of psoriatic arthritis (PsA)
  • Understand the magnitude of psoriatic arthritis (PsA) population by its severity-specific cases of psoriatic arthritis (PsA)
  • Psoriatic arthritis (PsA) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • Psoriatic arthritis (PsA) epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Table of Contents

1. Key Insights2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
3.1. Market Share (%) Distribution of PsA in 2019
3.2. Market Share (%) Distribution of PsA in 2032
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
5.1. Introduction
5.2. Clinical Manifestations
5.3. Classification
5.4. Risk Factors
5.5. Pathogenesis
5.6. Diagnosis
5.7. Differential Diagnosis
5.8. Treatment and Management
5.8.1. ACR/NPF Recommendations for PsA
5.8.2. Summary of differences in recommendations
5.8.3. EULAR Recommendations
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Prevalence of PsA in the 7MM
6.3. Assumption and Rationale
6.4. The United States
6.4.1. Prevalent cases of PsA in the United States
6.4.2. Diagnosed Cases of PsA in the United States
6.4.3. Gender-specific Cases of PsA in the United States
6.4.4. Age-specific Cases of PsA in the United States
6.4.5. Severity-specific Cases of PsA in the United States
6.5. EU5
6.5.1. Total Prevalent Cases of PsA in the EU5
6.5.2. Germany
6.5.2.1. Diagnosed Cases of PsA in Germany
6.5.2.2. Gender-specific Cases of PsA in Germany
6.5.2.3. Age-specific Cases of PsA in Germany
6.5.2.4. Severity-specific Cases of PsA in Germany
6.5.3. France
6.5.3.1. Diagnosed Cases of PsA in France
6.5.3.2. Gender-specific Cases of PsA in France
6.5.3.3. Age-specific Cases of PsA in France
6.5.3.4. Severity-specific Cases of PsA in France
6.5.4. Italy
6.5.4.1. Diagnosed Cases of PsA in Italy
6.5.4.2. Gender-specific Cases of PsA in Italy
6.5.4.3. Age-specific Cases of PsA in Italy
6.5.4.4. Severity-specific Cases of PsA in Italy
6.5.5. Spain
6.5.5.1. Diagnosed Cases of PsA in Spain
6.5.5.2. Gender-specific Cases of PsA in Spain
6.5.5.3. Age-specific Cases of PsA in Spain
6.5.5.4. Severity-specific Cases of PsA in Spain
6.5.6. The United Kingdom
6.5.6.1. Diagnosed Cases of PsA in the UK
6.5.6.2. Gender-specific Cases of PsA in the UK
6.5.6.3. Age-specific Cases of PsA in the UK
6.5.6.4. Severity-specific Cases of PsA in the UK
6.6. Japan
6.6.1. Prevalent cases of PsA in Japan
6.6.2. Diagnosed Cases of PsA in Japan
6.6.3. Gender-specific Cases of PsA in Japan
6.6.4. Age-specific Cases of PsA in Japan
6.6.5. Severity-specific Cases of PsA in Japan
7. Patient Journey of Psoriatic Arthritis8. SWOT Analysis9. KOL Views10. Unmet Needs11. Market Access12. Acronyms and Abbreviations
13. Appendix
13.1. Bibliography
13.2. Report Methodology
14. Publisher Capabilities15. Disclaimer16. About the Publisher
List of Tables
Table 1: Summary of PsA, Epidemiology, and Key Events (2019-2032)
Table 2: Role of HLA Genes in PsA
Table 3: Role of non-HLA Genes in PsA
Table 4: CASPAR Criteria
Table 5: Moll and Wright Classification
Table 6: Operational Definition of Classification of PsA
Table 7: Suggested Diagnostic Algorithm
Table 8: Clinical Characteristics of Different Types of Arthritis That can aid Differential Diagnosis
Table 9: 2018 ACR/NPF Recommendations for the Initial Treatment for Active PsA who are OSM- and Other Treatment-naive
Table 10: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With a TNFi Biologics
Table 11: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With an IL-17i or an IL-12/23i Biologics
Table 12: 2018 ACR/NPF Recommendations for PsA Including Treat-to-target, Active Axial Disease, Enthesitis, or Active IBD
Table 13: 2018 ACR/NPF Recommendations for PsA and Comorbidities, Including Concomitant Diabetes and Recurrent Serious Infections
Table 14: 2018 ACR/NPF Recommendations for Non-pharmacologic Interventions in Patients With Active PsA Regardless of Pharmacologic Treatment Status
Table 15: Summary of Differences in Recommendations
Table 16: 2019 EULAR Overarching Principles
Table 17: 2019 EULAR Recommendations for the Pharmacological Management of PsA
Table 18: Total Prevalent Cases of PsA in the 7MM in 000’s (2019-2032)
Table 19: Prevalent cases of PsA in the United States in 000’s (2019-2032)
Table 20: Diagnosed Cases of PsA in the United States in 000’s (2019-2032)
Table 21: Gender-specific Cases of PsA in the United States in 000’s (2019-2032)
Table 22: Age-specific Cases of PsA in the United States in 000’s (2019-2032)
Table 23: Severity-specific cases of PsA in the United States in 000’s (2019-2032)
Table 24: Prevalent Cases of PsA in the EU5 in 000’s (2019-2032)
Table 25: Diagnosed cases of PsA in Germany in 000’s (2019-2032)
Table 26: Gender-specific Cases of PsA in Germany in 000’s (2019-2032)
Table 27: Age-specific Cases of PsA in Germany in 000’s (2019-2032)
Table 28: Severity-specific cases of PsA in Germany in 000’s (2019-2032)
Table 29: Diagnosed cases of PsA in France (2019-2032)
Table 30: Gender-specific Cases of PsA in France in 000’s (2019-2032)
Table 31: Age-specific Cases of PsA in France in 000’s (2019-2032)
Table 32: Severity-specific cases of PsA in France (2019-2032)
Table 33: Diagnosed cases of PsA in Italy in 000’s (2019-2032)
Table 34: Gender-specific Cases of PsA in Italy in 000’s (2019-2032)
Table 35: Age-specific Cases of PsA in Italy in 000’s (2019-2032)
Table 36: Severity-specific cases of PsA in Italy in 000’s (2019-2032)
Table 37: Diagnosed cases of PsA in Spain in 000’s (2019-2032)
Table 38: Gender-specific Cases of PsA in Spain in 000’s (2019-2032)
Table 39: Age-specific Cases of PsA in Spain in 000’s (2019-2032)
Table 40: Severity-specific cases of PsA in Spain in 000’s (2019-2032)
Table 41: Diagnosed cases of PsA in the UK in 000’s (2019-2032)
Table 42: Gender-specific Cases of PsA in the UK in 000’s (2019-2032)
Table 43: Age-specific Cases of PsA in the UK in 000’s (2019-2032)
Table 44: Severity-specific cases of PsA in the UK in 000’s (2019-2032)
Table 45: Prevalent cases of PsA in Japan in 000’s (2019-2032)
Table 46: Diagnosed Cases of PsA in Japan in 000’s (2019-2032)
Table 47: Gender-specific Cases of PsA in Japan in 000’s (2019-2032)
Table 48: Age-specific Cases of PsA in Japan in 000’s (2019-2032)
Table 49: Severity-specific cases of PsA in Japan in 000’s (2019-2032)
List of Figures
Figure 1: Clinical Presentations of PsA
Figure 2: Classification of PsA
Figure 3: Risk Factors
Figure 4: Role of Obesity and Risk of Cardiovascular Comorbidities in PsA patients
Figure 5: Key cell Types and Secretion of key Inflammatory Mediators in PsA
Figure 6: Adaptive and Innate Immune Cells and Activated Pathways in PsA
Figure 7: Diagnosis of PsA
Figure 8: Radiographic Features of PsA
Figure 9: Differential Diagnosis
Figure 10: Pharmacologic, Non-pharmacologic, and Symptomatic Therapies for PsA
Figure 11: The EULAR 2019 Algorithm for Treatment of PsA With Pharmacological Non-topical Treatments
Figure 12: PsA Treatment Pathway Following Inadequate Response to DMARDs (NICE)
Figure 13: Total Prevalent Cases of PsA in the 7MM in 000’s (2019-2032)
Figure 14: Prevalent cases of PsA in the United States in 000’s (2019-2032)
Figure 15: Diagnosed Cases of PsA in the United States in 000’s (2019-2032)
Figure 16: Gender-specific cases of PsA in the United States in 000’s (2019-2032)
Figure 17: Age-specific Cases of PsA in the United States in 000’s (2019-2032)
Figure 18: Severity-specific Cases of PsA in the United States in 000’s (2019-2032)
Figure 19: Prevalent Cases of PsA in the EU5 in 000’s (2019-2032)
Figure 20: Diagnosed cases of PsA in Germany in 000’s (2019-2032)
Figure 21: Gender-specific cases of PsA in Germany in 000’s (2019-2032)
Figure 22: Age-specific Cases of PsA in Germany in 000’s (2019-2032)
Figure 23: Severity-specific Cases of PsA in Germany in 000’s (2019-2032)
Figure 24: Diagnosed cases of PsA in France (2019-2032)
Figure 25: Gender-specific cases of PsA in France in 000’s (2019-2032)
Figure 26: Age-specific Cases of PsA in France in 000’s (2019-2032)
Figure 27: Severity-specific Cases of PsA in France (2019-2032)
Figure 28: Diagnosed cases of PsA in Italy in 000’s (2019-2032)
Figure 29: Gender-specific cases of PsA in Italy in 000’s (2019-2032)
Figure 30: Age-specific Cases of PsA in Italy in 000’s (2019-2032)
Figure 31: Severity-specific Cases of PsA in Italy in 000’s (2019-2032)
Figure 32: Diagnosed cases of PsA in Spain in 000’s (2019-2032)
Figure 33: Gender-specific cases of PsA in Spain in 000’s (2019-2032)
Figure 34: Age-specific Cases of PsA in Spain in 000’s (2019-2032)
Figure 35: Severity-specific Cases of PsA in Spain in 000’s (2019-2032)
Figure 36: Diagnosed cases of PsA in the UK in 000’s (2019-2032)
Figure 37: Gender-specific cases of PsA in the UK in 000’s (2019-2032)
Figure 38: Age-specific Cases of PsA in the UK in 000’s (2019-2032)
Figure 39: Severity-specific Cases of PsA in the UK in 000’s (2019-2032)
Figure 40: Prevalent cases of PsA in Japan in 000’s (2019-2032)
Figure 41: Diagnosed Cases of PsA in Japan in 000’s (2019-2032)
Figure 42: Gender-specific cases of PsA in Japan in 000’s (2019-2032)
Figure 43: Age-specific Cases of PsA in Japan in 000’s (2019-2032)
Figure 44: Severity-specific Cases of PsA in Japan in 000’s (2019-2032)

Related Topics

Related Reports

Psoriatic Arthritis Therapeutics - Global Strategic Business Report - Product Image

Psoriatic Arthritis Therapeutics - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032 - Product Image

Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032

  • Report
  • 170 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Psoriatic Arthritis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Psoriatic Arthritis Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 85 Pages
  • Global
From
Psoriatic Arthritis Treatment Global Market Report 2024 - Product Image

Psoriatic Arthritis Treatment Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.